Baird raised the firm’s price target on PTC Therapeutics (PTCT) to $48 from $44 and keeps an Outperform rating on the shares. The firm said 3Q24 revenue exceeded expectations meaningfully, in part due to steady sales of Emflaza despite it now having generic competition.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Reports Strong Q3 2024 Performance
- PTC Therapeutics Raises Revenue Guidance for 2024
- PTC Therapeutics reports Q3 EPS ($1.39), consensus ($1.44)
- PTC Therapeutics sees 2024 revenue $750M-$800M, consensus $734.43M
- PTC Therapeutics announces FDA acceptance of Translarna NDA resubmission